

Advanced Non-Small Cell Lung Cancer: Retrospective Study of Prognostic Factors

Hend A EL-Hadaad¹, Yasser M Saleh¹, Hanan A Wahba¹ and Magda A Ahmad²

¹Department of Clinical Oncology & Nuclear Medicine, Mansoura University, Egypt

²Chest Medicine department, Mansoura University, Egypt

*Corresponding author: Dr. Hend Ahmed El-Hadaad, MD, Faculty of medicine, University of Mansoura, Egypt, Tel: +20124272772; E-mail: hend_am@mans.edu.eg

Received date: March 09, 2017; Accepted date: March 28, 2017; Published date: March 31, 2017

Copyright: © 2017 EL-Hadaad HA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: The objective of the study is to investigate and improve our understanding of the impact of several potential prognostic factors on overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC).

Methods: Records of patients with advanced NSCLC (stage IIIB, IV) received first-line chemotherapy were reviewed. Age, gender, Eastern Cooperative Oncology Group performance status (ECOGPS), stage, histologic type, smoking status, leucocytic count, type of chemotherapy, albumin and hemoglobin level were evaluated for their prognostic significance in multivariate analysis.

Results: A total of 140 patients with advanced NSCLC treated with first-line chemotherapy were identified. The median age was 54 (range from 35-83) years. The majority of patients were male (72%), had stage IIIB (67%) and were in PS 0or1 (75.7%). Forty-six percent had adenocarcinoma. Most patients were smokers (85%) and received platinum-based chemotherapy (78.6%). 1-year OS was 39.3% with median survival time of 10 months (95% CI: 7.95-12). ECOGPS of 2 (P=0.04), squamous histology (P=0.03), elevated leucocytic count (P=0.02), low hemoglobin level (P=0.02), smoking (P=0.03), low albumin level (P=0.05) and stage IV (P=0.01) were found to be independent prognostic factors for poor survival in multivariate analysis. While age (P=0.23), sex (P=1) and type of chemotherapy whether platinum-based or not (P=0.8) were insignificant factors for survival.

Conclusion: From this study, we concluded that prognostic factors as smoking, ECOG PS of 2, squamous histology, stage IV, high leucocytic count, low hemoglobin level, low albumin level are found to have a significant impact on the survival while, gender, age, and type of chemotherapy are not. However, these results and additional information regarding prognostic factors in patients with advanced NSCLC in prospective studies should be validated.

Keywords Lung cancer; Non-small cell lung cancer (NSCLC); Overall survival (OS); Prognostic factors

Introduction

Lung cancer is one of the most commonly diagnosed cancers and is the leading cause of death from cancer in the United States and Europe [1,2]. Lung cancer is divided into two major classes: 1) Non-small cell lung cancer (NSCLC), accounts for 85% and 2) Small cell lung cancer (SCLC), accounts for 15% [3]. Based on histology NSCLC is classified into squamous cell cancer (SCC) (29%), adenocarcinoma (32%) and rest have other subtypes [4]. Unfortunately, about 56% of patients with lung cancer at the time of diagnosis have advanced disease [5]. The outcome of patients with advanced NSCLC generally is poor, a large meta-analysis demonstrated a 2-month increase in median survival after platinum-based therapy and an absolute 10% improvement in the 1-year survival rate compared with best supportive care [6].

Prognostic factors can contribute to clinical decision making help to individualize treatment in advanced stages of NSCLC. In a review of the literature published between 1990 and 2001, Brundage et al. [7] criticized the great variations in the published literature. There are

variations in study populations, in the type of statistical analysis and the type of treatment.

The aim of our study is to investigate and improve our understanding of the impact of several potential prognostic factors on overall survival (OS) in patients with advanced NSCLC.

Patients and Methods

Records of all patients with advanced NSCLC (stage IIIB, IV) attended to Clinical Oncology and Nuclear Medicine Department between 2004-2013 were reviewed. Patients who never received any chemotherapy were excluded. Demographic and clinical data included: age, gender, histologic tumor type, stage of disease, smoking status, ECOG performance status (PS), type of chemotherapy received were collected. Also, laboratory investigations including hemoglobin level, leucocytic count, and albumin level were obtained from medical records. Recorded data of subjective, objective responses and date of death or last follow-up were reviewed.

Overall survival (OS) was defined as the period between date of diagnosis and date of death or last follow-up. Age, gender, PS, stage, histologic type, smoking status, leucocytic count, type of


chemotherapy, albumin and hemoglobin level were evaluated for their prognostic significance in multivariate analysis.

Statistical Methods

The data were coded and entered into a computer using SPSS version 15.0. Kaplan-Meier test was used to estimate overall survival. Multivariate analysis for prognostic factors which affect survival was determined using Mann-Whitney test where in P<0.05 was considered to indicate statistical significance.

Results

A total of 140 patients with advanced NSCLC treated with first-line chemotherapy were identified. Patient's characteristics are summarized in Table 1. The median age was 54 (range from 35-83) years. The majority of patients were male (72%), had stage IIIB (67%) and were in PS 0 or 1 (75.7%). Forty-six percent had adenocarcinoma. Most patients were smokers (85%) and received platinum-based chemotherapy (78.6%). 1-year OS was 39.3% with median survival time of 10 months (95% CI: 7.95-12%) (Figure 1).



Character	No	%
Age		
Median (range)	54 (35-83)years	
≤ 60 years	88	62.9
> 60years	52	37.1
Gender		
Male	101	72.1
Female	39	27.9
ECOG PS		
0-1	106	75.7
2	34	24.3
Histology		
Adenocarcinoma	65	46.4

Squamous cell carcinoma	35	25
Others	40	28.6
Smoking status		
Smokers	119	85
Non-smokers	21	15
Stage		
IIIB	94	67.1
IV	46	32.9
Hemoglobin level		
<10g/dl	50	35.7
≥ 10g/dl	90	64.3
Leucocytic count		
≤ 10.5 × 10 ⁹ /L	92	65.7
>10.5 × 10 ⁹ /L	48	34.3
Type of chemotherapy		
Platinum-based	110	78.6
Non platinum-based	30	21.4
Albumin level		
< 3.5 g/dl	47	33.6
≥ 3.5 g/dl	93	66.4

Table 1: Patients characteristics

ECOGPS of 2 (P=0.04), squamous histology (P=0.03), elevated leucocytic count (P=0.02), low hemoglobin level (P=0.02), smoking (P=0.03), low albumin level (P=0.05) and stage IV (P=0.01) were found to be independent prognostic factors for poor survival in multivariate analysis. While age (P=0.23), sex (P=1) and type of chemotherapy whether platinum-based or not (P=0.8) were insignificant factors for survival.

Discussion

One advantage of this study is a uniform patients population as regard stage, diagnosis and treatment as most patients (78.6%) received platinum-based chemotherapy but its weakness is due to a retrospective nature. 1-year OS rate was 39.3% comparable to that reported in previous studies [6,8]. Although 2-drugs regimens are better than single agent, 3-drugs regimens are not better in terms of improving OS compared with 2-drugs combinations [9]. Current research has shifted to targeted systemic therapy that selectively targets cancer cells so reducing toxicity [10]. Targeted agents as erlotinib and bevacizumab have successes in enhancing survival [8,11].

Patients with poorer PS, stage IV disease, high leucocytic count, low albumin level, anemia, squamous histology, smoking had significantly worse overall survival.

It is accepted generally that PS and stage are associated with poorer outcomes [7]. Low serum albumin is associated with ongoing systemic

inflammation [12]. Systemic inflammation has been found to predict poor outcome in patients with different cancers including lung cancer [13]. Smoking has been described as a prognostic factor in lung cancer [14-17]. Experimental studies have shown that nicotine inhibits apoptosis induced by gemcitabine, cisplatin and paclitaxel [18].

The prognostic significance of complete blood count findings has been reported less consistently [19-22]. None of the previous studies observed that both the pretreatment leucocytic count and hemoglobin level were of independent prognostic value but our results highlight the prognostic importance of both values in OS. Anemia may reflect cachexia associated with cancer, especially metastatic cancer.

Worse survival in patients with high leucocytic count may reflect either a greater burden of tumor cells within the bone marrow or a possible concomitant subclinical infection or the effect of a yet un described chemokine or cytokine secreted by the tumor into the circulation [23].

No significant differences in OS were found based on platinum therapy in multivariate analysis, indicating that the effect of prognostic factors on OS was more profound than the benefit from platinum-based therapy. Age and sex did not significantly affect OS, comparable to that observed by others [23-25]. While Jafri et al. [26] reported that younger age (<60 years) had significant impact on OS, one explanation could be that patients diagnosed at a young age may have a more biologically aggressive disease so more metastatic sites and worse outcome. Female gender had good prognosis in a study conducted by Henschke et al. [27]. However, there is a continuous need to identify specific and sensitive biomarkers that may predict prognosis in NSCLC as the Notch signaling pathway [28].

Conclusion

From this study, we concluded that prognostic factors as smoking, ECOG PS of 2, squamous histology, stage IV, high leucocytic count, low hemoglobin level, and low albumin level were found to have a significant impact on the survival, while, gender, age, and type of chemotherapy were not. However, these results and additional information regarding prognostic factors in patients with advanced NSCLC in prospective studies should be validated.

References

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics 2012. *CA Cancer. J Clin* 62:10-29.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. *Ann Oncol* 18:581-592.
3. Herbst R, Heymach J, Lippman S (2008) Lung cancer. *NEJM* 359:1367-1380.
4. Wabaha M, Boroumand N, Castro C, El-zeky F, Eltorkey M (2007) Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. *Ann Diagn Pathol* 11: 89-96.
5. Howlader N, Noone AM, Krapcho M (2009) SEER Cancer Statistics Review 1975-2009 (Vintage: Populations). Bethesda, MD: National Cancer Institute.
6. No authors listed (1995) Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. *Br Med J* 311: 899-909.
7. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. *Chest* 122:1037-1057.
8. Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, et al. (2005) Randomized Phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group trial: E4599. *J Clin Oncol* 23:31-33.
9. Bunn PA Jr (2002) Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why. *J Clin Oncol* 20: 23s-33s.
10. Johnson DH (2003) Targeted therapy in non-small cell lung cancer: myth or reality. *Lung Cancer* 41:S3-S8.
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T (2005) Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 353: 123-132.
12. Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdle CS, et al. (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. *BJC* 87:264-267.
13. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, et al. (2008) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. *J Thorac Cardiovasc Surg* 137: 425-428.
14. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G (2004) Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. *Chest* 126:347-351.
15. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK (2006) Smoking affects treatment outcome in patients with advanced non small cell lung cancer. *Cancer* 106:2428-2436.
16. Itaya T, Yamaoto N, Ando M, Ebisawa A, Nakamura Y, et al. (2007) Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. *Cancer Sci* 98: 226-230.
17. Janjigian YY, McDonnell K, Kris MG, Shen R, Sima CS, et al. (2008) Pack-years of cigarette smoking as a predictor of survival in 2,013 patients with stage IIIb/IV non-small cell lung cancer (NSCLC). *ASCO*.
18. Dasgupta P, Kinkade R, Joshi B, DeCook C, Haura E, et al. (2006) Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. *Proc Natl Acad Sci USA* 103:6332-6337.
19. Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, et al. (1996) Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. *Lung Cancer* 15: 67-77.
20. Watine J (1998) Further comments on "A practical prognostic index for inoperable non-small-cell lung cancer": a clinical biologist's point of view. *J Cancer Res Clin Oncol* 124:581-583.
21. Wigren T (1997) Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. *Radiother Oncol* 44: 9-15.
22. Ferrigno D, Buccheri G (2003) Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. *Monaldi Arch Chest Dis* 59:193-198.
23. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, et al. (2006) A prognostic model for advanced stage non-small cell lung cancer. Pooled analysis of north central cancer treatment group trials. *Cancer* 107:781-92.
24. Koch A, Fohlin H, Sorenson S (2009) Prognostic significance of c-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. *J Thorac Oncol* 4:326-332.
25. Tibaldi C, Vasile E, Bernardini I, Orlandini C, Andreuccetti M, et al. (2008) Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. *J Cancer Res Clin Oncol* 134:1143-1149.
26. Jafri SH, Shi R, Mills G (2013) Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. *BMC Cancer* 13:158.
27. Henschke CI, Yankelevitz DF, Libby DM (2006) Survival of patients with stage I lung cancer detected on CT screening. *N Engl J Med* 355:1763-1771.

-
28. Wojtkiewicz JP, Eliazewicz A, Kowalczyk O, Niklinska W, Chraiiewicz R, et al. (2017) Prognostic significance of Notch ligands in patients with non-small cell lung cancer. *Oncology Letters* 506:10.

This article was originally published in a special issue, entitled: "**Lung Cancer Diagnosis & Treatment**", Edited by Alfio Ferlito